Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI response includes multiple claims not supported by the label (absent_from_label) and one contradicted claim, with a minority of statements aligned to the label. Overall alignment is poor.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin.
12.1
Lipitor inhibits the enzyme HMG-CoA reductase.
12.1
By reducing cholesterol production, Lipitor helps to lower LDL cholesterol levels.
12.1; 1.1
Lipitor reduces the risk of heart disease.
1.1
Lipitor is generally not recommended for pregnant or breastfeeding women.
4.3; 4.4
Lipitor can increase the risk of muscle disease, including rhabdomyolysis.
5.1
Unsupported Statements
Lipitor can affect the absorption of vitamin K in patients with normal kidney function.
No label information about vitamin K absorption.
Lipitor can affect the absorption of vitamin D in patients with chronic kidney disease.
No label information about vitamin D absorption.
Lipitor reduces the absorption of fat-soluble vitamins (A, E, and K).
No label information about fat-soluble vitamin absorption.
Inhibition of HMG-CoA reductase by Lipitor can decrease the production of coenzyme Q10 (CoQ10).
No label information about CoQ10 production.
Coenzyme Q10 (CoQ10) is essential for the absorption of fat-soluble vitamins.
No label information about CoQ10's role in vitamin absorption.
Taking Lipitor with food can help to reduce the risk of vitamin deficiencies.
No label guidance linking food intake with vitamin deficiency risk.
Taking a vitamin supplement may be beneficial if you are taking Lipitor to ensure adequate nutrient intake.
No label guidance recommending vitamin supplements with Lipitor.
Regular blood tests can help to monitor vitamin levels and ensure that you are not deficient in essential nutrients.
Label discusses monitoring liver enzymes and CPK, not vitamins.
Contradictions
Low
AI Statement
Lipitor may require dose adjustments in patients with kidney disease.
Label Reference
2.5
Low
AI Statement
Lipitor can be used in patients with liver disease, but it may require dose adjustments.
Label Reference
5.2; 4.1
Important Omissions
Monitoring recommendations for liver function tests (ALT/AST) and creatine phosphokinase (CPK) are not reflected in the AI claims, though label requires LFTs and CPK monitoring.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI claims align with key safety topics (muscle and liver risk) but include multiple vitamin-absorption and CoQ10-related assertions that are not label-supported; overall material safety risks are not amplified beyond label-provided concerns.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Substantial number of absent_from_label statements and a couple of contradictions; limited focus on label-supported indications, dosing in renal impairment, and hepatic monitoring.
Suggested Improvement
Constrain claims to label-supported information; remove vitamin absorption and CoQ10 absorption/production assertions; clearly distinguish between fully supported, partially supported, unsupported, and contradictory statements; ensure dosing and liver/kidney disease guidance reflect label specifics.